Skip to main content
SpringerLink
Log in

The Occurrence of Gastrointestinal Stromal Tumors and Second Malignancies

  • Brief Communication
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy of the gastrointestinal tract. GISTs may coexist with different types of cancer, either synchronous or metachronous. The frequency of this association and the spectrum of neoplasms involved have not been sufficiently analyzed; most of publications describe a single case report and rare case series. In the absence of definitive data, it could be interesting to compare the frequency of the occurrence of GIST and second malignancies in literature.

Methods

A review of all case series that reported the frequency of the occurrence of GIST and synchronous second malignancies were considered.

Results

Six retrospective case series were considered, including 440 GIST patients; of these, there were 64 (14.5 %) patients with other synchronous second malignancies. Median age was 67 years, median GIST size was 3.91 cm (range 3.0–4.79 cm), and all cases (100.0 %) were CD117 and CD34 positive. According to the risk categories, 35.2 % of patients had a very low risk, 24.0 % a low risk, 27.6 % an intermediate risk, and 13.2 % a high risk.

Conclusions

Regarding the occurrence of GISTs and synchronous second malignancies, we can consider it as more common than it has been considered. Differently, concerning the topic of the incidence of second primary malignancies (SPMs) and metachronous second malignancies in pre-imatinib and after-imatinib era, we can consider it as a clinically relevant topic; according to the present knowledge, the main cause for the increased incidence of SPMs in the imatinib era is explained by the increased survival of patients with metastatic GISTs and therefore more time available to develop SPMs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol. 2006;23:120–9.

    Article  PubMed  Google Scholar 

  2. Nishida T, Hirota S, Taniguchi M, Hashimoto K, Isozaki K, Nakamura H, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet. 1998;19:323–4.

    Article  CAS  PubMed  Google Scholar 

  3. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc. 1999;74:543–52.

    Article  CAS  PubMed  Google Scholar 

  4. Sugimura T, Fujimura S, Baba T. Tumor production in the glandular stomach and alimentary tract of the rat by N-methyl-N′-nitro-N-nitrosoguanidine. Cancer Res. 1970;30:455–65.

    CAS  PubMed  Google Scholar 

  5. Cohen A, Geller SA, Horowitz I, Toth LS, Werther JL. Experimental models for gastric leiomyosarcoma. The effects of N-methyl-N′-nitro-N-nitrosoguanidine in combination with stress, aspirin, or sodium taurocholate. Cancer. 1984;53:1088–92.

    Article  CAS  PubMed  Google Scholar 

  6. Kaffes A, Hughes L, Hollinshead J, Katelaris P. Synchronous primary adenocarcinoma, mucosa-associated lymphoid tissue lymphoma and a stromal tumor in a Helicobacter pyloriinfected stomach. J Gastroenterol Hepatol. 2002;17:1033–6.

    Article  PubMed  Google Scholar 

  7. Lin YL, Tzeng JE, Wei CK, Lin CW. Small gastrointestinal stromal tumor concomitant with early gastric cancer: a case report. World J Gastroenterol. 2006;12:815–7.

    PubMed Central  PubMed  Google Scholar 

  8. Wronski M, Ziarkiewicz-Wroblewska B, Gornicka B, Cebulski W, Slodkowski M, Wasiutynski A, et al. Synchronous occurrence of gastrointestinal stromal tumors and other primary gastrointestinal neoplasms. World J Gastroenterol. 2006;12:5360–2.

    PubMed Central  PubMed  Google Scholar 

  9. Ferreira SS, Werutsky G, Toneto MG, Alves JM, Piantá CD, Breunig RC, et al. Synchronous gastrointestinal stromal tumors (GIST) and other primary cancers: case series of a single institution experience. Int J Surg. 2010;8:314–7.

    Article  PubMed  Google Scholar 

  10. Gonçalves R, Linhares E, Albagli R, Valadão M, Vilhena B, Romano S, et al. Occurrence of other tumors in patients with GIST. Surg Oncol. 2010;19:e140–3.

    Article  PubMed  Google Scholar 

  11. Giuliani J, Marzola M, Indelli M, Aliberti C, Sartori S, Lanza G, et al. Gastrointestinal stromal tumors and other malignancies: a case series. J Gastrointest Canc. 2012;43:634–47.

    Article  Google Scholar 

  12. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70–83.

    Article  PubMed  Google Scholar 

  13. AbdullGaffar B. Gastrointestinal stromal tumors and extra-gastrointestinal tract neoplasms. South Med J. 2010;103:1004–8.

    Article  PubMed  Google Scholar 

  14. Kanda T, Ishikawa T, Hirota S, Yajima K, Kosugi S, Ohashi M, et al. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy. Jpn J Clin Oncol. 2012;42:578–85.

    Article  PubMed  Google Scholar 

  15. Phan K, Martires K, Kurlander DE, Gaddipati K, Xavier M. The incidence of second primary malignancies after gastrointestinal stromal tumor before and after the introduction of imatinib mesylate. Transl Cancer Res. 2013. doi:10.3978/j.issn.2218-676X.2013.07.04.

    Google Scholar 

  16. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139–45.

    CAS  PubMed  Google Scholar 

  17. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925–32.

    CAS  PubMed  Google Scholar 

  18. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–6.

    Article  CAS  PubMed  Google Scholar 

  19. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;97:2440–8.

    Article  CAS  PubMed  Google Scholar 

  20. Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg. 2006;202:623–9.

    Article  PubMed  Google Scholar 

  21. Artinyan A, Kim J, Soriano P, Chow W, Bhatia S, Ellenhorn JD. Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities. Cancer Epidemiol Biomarkers Prev. 2008;17:2194–201.

    Article  CAS  PubMed  Google Scholar 

  22. Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011;118:4353–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29:2904–9.

    Article  CAS  PubMed  Google Scholar 

  25. Giuliani J, Bonetti A. Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate. Chin J Cancer Res. 2013;25:486–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  26. Pandurengan RK, Dumont AG, Araujo DM, Ludwig JA, Ravi V, Patel S, et al. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol. 2010;21:2107–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Kramer K, Wolf S, Mayer B, Schmidt SA, Agaimy A, Henne-Bruns D, et al. Frequence, spectrum and prognostic impact of additional malignancies in patients with gastrointestinal stromal tumors. Neoplasia. 2015;17:134–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Kang DY, Park CK, Choi JS, Jin SY, Kim HJ, Joo M, et al. Multiple gastrointestinal stromal tumors: clinicopathologic and genetic analysis of 12 patients. Am J Surg Pathol. 2007;31:224–32.

    Article  PubMed  Google Scholar 

  29. Ponti G, Luppi G, Martorana D, Rossi G, Losi L, Bertolini F, et al. Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting. Oncol Rep. 2010;23:437–44.

    CAS  PubMed  Google Scholar 

  30. Maiorana A, Fante R, Maria Cesinaro A, Adriana Fano R. Synchronous occurrence of epithelial and stromal tumors in the stomach: a report of 6 cases. Arch Pathol Lab Med. 2000;124:682–6.

    CAS  PubMed  Google Scholar 

  31. Kanda T. Criminal or bystander: imatinib and second primary malignancy in GIST patients. Chin J Cancer Res. 2013;25:490–2.

    PubMed Central  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Department of Oncology, Mater Salutis Hospital, ASL 21 della Regione Veneto, Via Gianella 1-37045, Legnago, VR, Italy

    Jacopo Giuliani & Andrea Bonetti

Authors
  1. Jacopo Giuliani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Bonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacopo Giuliani.

Additional information

Authorship

Jacopo Giuliani and Andrea Bonetti contributed equally to (1) conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giuliani, J., Bonetti, A. The Occurrence of Gastrointestinal Stromal Tumors and Second Malignancies. J Gastrointest Canc 46, 408–412 (2015). https://doi.org/10.1007/s12029-015-9759-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-015-9759-3

Keywords

Search

Navigation